TMCnet News
Dr. Victor Levin, Founder of the Society of Neuro-Oncology, Joins Nativis Medical and Science Advisory BoardNativis, Inc., a Seattle-based life sciences company developing non-invasive, safe and highly effective medical device therapies for cancers and other serious diseases, announced today that Dr. Victor Levin has joined the company's Medical and Science Advisory Board. Dr. Levin will be responsible for providing guidance on Nativis' clinical and preclinical programs. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160524005214/en/ 
Dr. Victor Levin, Nativis Medical and Science Advisory Board (Photo: Business Wire) "As the 'Father of Neuro-Oncology,' we are deeply honored to have Dr. Levin join our world renowned advisory board," stated Chris Rivera, Nativis' chairman and chief executive officer. "We look forward to leveraging his extensive background and experience with that of the rest of the board as we move forward with our clinical development programs." "I'm truly excited to join Nativis' advisory board and look forward to collaborating with the other key neuro-oncology opinion leaders to help guide the company as they continue to develop their non-invasive technology," said Dr. Victor Levin. "I believe that The Voyager system has the potential to revolutionize the treatment of cancer and other serious diseases thrugh its novel use of radio frequency energy to disrupt the division of cancer cells." Dr. Levin joins other global neuro-oncology key opinion leaders on the Nativis Scientific and Medical Advisory Board, including:
A world-renowned expert in brain tumor research and treatment, Dr. Levin is currently Emeritus Professor of Neuro-Oncology at the University of Texas M. D. Anderson Cancer Center and is the former Chairman of the Department of Neuro-Oncology and Director of the Multidisciplinary Brain Tumor Center. Prior to joining the University of Texas, Dr. Levin was a professor at the University of California, San Francisco in the Departments of Neurosurgery and Pharmaceutical Chemistry as well as Chief of the Neuro-Oncology Service of the Brain Tumor Research Center. He is also the founder and first president (1995-97) of the Society for Neuro-Oncology. Dr. Levin's most recent laboratory research efforts involved the development of novel cell-based 2-dimensional and 3-dimensional assays to speed the development of new combinations that selectively inhibit signal transduction pathways critical to tumor proliferation. His research includes pharmacokinetics studies of anticancer drugs in the brain and cerebrospinal fluid, experimental and clinical studies of chemotherapy during radiation therapy, chemotherapy regimens for the treatment of Gliomas, and studies of chemotherapy and radiation therapy for childhood Medulloblastoma and Ependymoma. Dr. Levin has authored more than 370 publications including the book, Cancer in the Nervous System. Dr. Levin received his M.D. from the University of Wisconsin-Madison and completed his residency in neurology and NINDS fellowship programs at Massachusetts General Hospital. About Nativis, Inc. Founded in 2002, Nativis, Inc. is a privately held life sciences company located in Seattle's South Lake Union biotech neighborhood. Nativis' mission is to improve the human and animal condition by providing non-invasive, safe and highly effective medical device therapies for cancers and other serious diseases. For more information, contact [email protected] or visit nativis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160524005214/en/ |
